TY - JOUR
T1 - Corrigendum to “American Association of Clinical Endocrinology Consensus Statement
T2 - Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update” [Endocrine Practice. 2026;32(4):473-518]
AU - Samson, Susan L.
AU - Vellanki, Priyathama
AU - Blonde, Lawrence
AU - Hirsch, Irl B.
AU - Hoang, Thanh D.
AU - Isaacs, Scott D.
AU - Izuora, Kenneth E.
AU - Low Wang, Cecilia C.
AU - Ooi, Cheow Peng
AU - Padilla, Blanca Iris
AU - Schulman-Rosenbaum, Rifka
AU - Twining, Christine L.
AU - Umpierrez, Guillermo E.
AU - Valencia, Willy Marcos
N1 - Publisher Copyright:
© 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2026/8
Y1 - 2026/8
N2 - Authors of the American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update. Endocr Pract. 2026 Apr;32(4):473-518. doi: 10.1016/j.eprac.2026.01.006. Epub 2026 Mar 17. PMID: 41842862 have identified an error and offer the following correction:1.Page 485, column 2, of the pdf of the document states:Page 485, column 2, of the pdf of the document states: “If a diagnosis of T1D is established, insulin treatment is needed. Individuals with LADA may not require insulin at the onset of disease if C-peptide is still ≥300 pmol/L (1.8 ng/mL),117 and there is the possibility of using other glucose-lowering agents (metformin, GLP-1 RA, DPP-4i, TZD, SGLT2i), but there is a lack of strong clinical evidence for benefit in this population.”
AB - Authors of the American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update. Endocr Pract. 2026 Apr;32(4):473-518. doi: 10.1016/j.eprac.2026.01.006. Epub 2026 Mar 17. PMID: 41842862 have identified an error and offer the following correction:1.Page 485, column 2, of the pdf of the document states:Page 485, column 2, of the pdf of the document states: “If a diagnosis of T1D is established, insulin treatment is needed. Individuals with LADA may not require insulin at the onset of disease if C-peptide is still ≥300 pmol/L (1.8 ng/mL),117 and there is the possibility of using other glucose-lowering agents (metformin, GLP-1 RA, DPP-4i, TZD, SGLT2i), but there is a lack of strong clinical evidence for benefit in this population.”
UR - https://www.scopus.com/pages/publications/105041391405
U2 - 10.1016/j.eprac.2026.05.025
DO - 10.1016/j.eprac.2026.05.025
M3 - Comment/debate
C2 - 42283653
AN - SCOPUS:105041391405
SN - 1530-891X
VL - 32
SP - 1332
JO - Endocrine Practice
JF - Endocrine Practice
IS - 8
ER -